{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:02:47Z","timestamp":1793037767432,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4147,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1093\/annonc\/mdn164","type":"journal-article","created":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:24:51Z","timestamp":1209601491000},"page":"1407-1416","source":"Crossref","is-referenced-by-count":198,"title":["Practical guidance for the management of aromatase inhibitor-associated bone loss"],"prefix":"10.1016","volume":"19","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tubiana-Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn164_bb0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors. Results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1093\/annonc\/mdn164_bb0015","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/cncr.21335","article-title":"Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Results from a subgroup in the Women's Health Initiative Observational Study","volume":"104","author":"Chen","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn164_bb0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdn164_bb0025","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0002-9343(03)00127-X","article-title":"The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer","volume":"114","author":"Greep","year":"2003","journal-title":"Am J Med"},{"key":"10.1093\/annonc\/mdn164_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.2003.03.088","article-title":"Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998","volume":"21","author":"Li","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0040","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group","volume":"351","author":"Clarke","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdn164_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/BD-2006-24109","article-title":"Aromatase inhibitors: changing the face of endocrine therapy for breast cancer","volume":"24","author":"Buzdar","year":"2005","journal-title":"Breast Dis"},{"key":"10.1093\/annonc\/mdn164_bb0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdn164_bb0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdn164_bb0065","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdn164_bb0070","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdn164_bb0075","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn164_bb0080","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women","volume":"332","author":"Cummings","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn164_bb0090","unstructured":"National Osteoporosis FoundationPhysician's Guide: Pharmacologic Options http:\/\/www.nof.org\/physguide\/pharmacologic.htm (4 October 2007, date last accessed)"},{"key":"10.1093\/annonc\/mdn164_bb0095","series-title":"Technical Report Series 921: Prevention and Management of Osteoporosis","first-page":"1","author":"World Health Organization","year":"2003"},{"key":"10.1093\/annonc\/mdn164_bb0100","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdn164_bb0105","first-page":"305S","article-title":"Rules of evidence and clinical recommendations on the use of antithrombotic agents","volume":"102","author":"Cook","year":"1992","journal-title":"Chest"},{"issue":"Suppl","key":"10.1093\/annonc\/mdn164_bb0110","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1378\/chest.95.2_Supplement.2S","article-title":"Rules of evidence and clinical recommendations on the use of antithrombotic agents","volume":"95","author":"Sackett","year":"1989","journal-title":"Chest"},{"key":"10.1093\/annonc\/mdn164_bb0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/17455057.3.4.441","article-title":"Managing aromatase inhibitor-associated bone loss in breast cancer","volume":"3","author":"Lipton","year":"2007","journal-title":"Women's Health"},{"key":"10.1093\/annonc\/mdn164_bb0120","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostate cancer\u2014a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0125","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"Suppl","key":"10.1093\/annonc\/mdn164_bb0130","first-page":"5s","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the \u2018Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial","volume":"24","author":"Coleman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0140","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0145","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0150","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1093\/annonc\/mdn164_bb0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00198-005-0027-4","article-title":"The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA)","volume":"17","author":"Siris","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623453","article-title":"Consensus development statement: who are candidates for prevention and treatment for osteoporosis?","volume":"7","author":"Lindsey","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S8756-3282(02)00919-5","article-title":"Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study","volume":"32","author":"Albrand","year":"2003","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdn164_bb0170","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdn164_bb0175","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0180","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","article-title":"A family history of fracture and fracture risk: a meta-analysis","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdn164_bb0185","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1532-5415.2004.52410.x","article-title":"Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures","volume":"52","author":"Taylor","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1093\/annonc\/mdn164_bb0190","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdn164_bb0195","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0200","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","article-title":"Oral glucocorticoid use is associated with an increased risk of fracture","volume":"15","author":"Steinbuch","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0205","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdn164_bb0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1513\/pats.200402-016MS","article-title":"Safety of inhaled corticosteroids","volume":"1","author":"Tattersfield","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1093\/annonc\/mdn164_bb0215","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.315.7112.841","article-title":"A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect","volume":"315","author":"Law","year":"1997","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdn164_bb0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0225","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2796.2003.01232.x","article-title":"Fracture risk associated with smoking: a meta-analysis","volume":"254","author":"Vestergaard","year":"2003","journal-title":"J Intern Med"},{"key":"10.1093\/annonc\/mdn164_bb0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1359\/jbmr.2005.20.1.131","article-title":"Risk factors for a first-incident radiographic vertebral fracture in women \u2265 65 years of age: the study of osteoporotic fractures","volume":"20","author":"Nevitt","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdn164_bb0235","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0240","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0360-3016(92)90895-O","article-title":"Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer","volume":"23","author":"Pierce","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdn164_bb0245","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jn\/136.6.1453","article-title":"Bone, body weight, and weight reduction: what are the concerns?","volume":"136","author":"Shapses","year":"2006","journal-title":"J Nutr"},{"key":"10.1093\/annonc\/mdn164_bb0250","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/07357900600633759","article-title":"Management of bone loss induced by aromatase inhibitors","volume":"24","author":"Gnant","year":"2006","journal-title":"Cancer Invest"},{"issue":"Suppl","key":"10.1093\/annonc\/mdn164_bb0255","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cncr.11149","article-title":"Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma","volume":"97","author":"Smith","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn164_bb0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/jc.2006-1272","article-title":"Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial","volume":"92","author":"Greenspan","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdn164_bb0265","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00198-007-0501-2","article-title":"Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study","volume":"19","author":"Nieves","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0270","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","article-title":"Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials","volume":"92","author":"Boonen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdn164_bb0275","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin D supplementation and the risk of fractures","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn164_bb0280","first-page":"232","article-title":"Long-term four-year exercise has a positive effect on menopausal risk factors: the Erlangen Fitness Osteoporosis Prevention Study","volume":"21","author":"Kemmler","year":"2007","journal-title":"J Strength Cond Res"},{"key":"10.1093\/annonc\/mdn164_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000333","article-title":"Exercise for preventing and treating osteoporosis in postmenopausal women","author":"Bonaiuti","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdn164_bb0290","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1188\/07.ONF.627-633","article-title":"Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy","volume":"34","author":"Schwartz","year":"2007","journal-title":"Oncol Nurs Forum"},{"key":"10.1093\/annonc\/mdn164_bb0295","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdn164_bb0300","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdn164_bb0305","first-page":"46S","article-title":"10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer","volume":"24","author":"Saarto","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdn164_bb0310","first-page":"S113","article-title":"The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month results","volume":"22","author":"Van Poznak","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"Suppl","key":"10.1093\/annonc\/mdn164_bb0315","first-page":"590s","article-title":"The role of bisphosphonates and bone health issues in Japanese breast cancer patients: efficacy of alendronate with aromatase inhibitors","volume":"24","author":"Yamada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0320","doi-asserted-by":"crossref","unstructured":"JE Lester SA Gutcher SP Ellis. Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: one-year results from the ARIBON studyChicago, IllinoisPresented at 43rd Annual Meeting of the American Society of Clinical Oncology, 1\u20135 June 2007(Abstr 553)","DOI":"10.1200\/jco.2007.25.18_suppl.553"},{"key":"10.1093\/annonc\/mdn164_bb0325","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdn164_bb0330","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0335","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn164_bb0340","unstructured":"N Bundred I Campbell R Coleman. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study)Nice, FrancePresented at 5th European Breast Cancer Conference, 21\u201325 March 2006 (Abstr 12)"},{"key":"10.1093\/annonc\/mdn164_bb0345","doi-asserted-by":"crossref","unstructured":"N Schenk A Lombart A Frassoladti. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (LET)Barcelona, SpainPresented at ECCO 14: the European Cancer Conference, 23\u201327 September 2007(Abstr 2008)","DOI":"10.1016\/S1359-6349(07)70770-X"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdn164_bb0350","first-page":"S36","article-title":"Zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST Trial)","volume":"106","author":"De Boer","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdn164_bb0355","first-page":"S233","article-title":"Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (LET)","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdn164_bb0360","first-page":"S8","article-title":"The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up","volume":"106","author":"Brufsky","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdn164_bb0365","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdn164_bb0370","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdn164_bb0375","series-title":"Zometa\u00ae (zoledronic acid) [Summary of Product Characteristics]","year":"2003"},{"key":"10.1093\/annonc\/mdn164_bb0380","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2474-3-11","article-title":"The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women","volume":"3","author":"Adachi","year":"2002","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1093\/annonc\/mdn164_bb0385","doi-asserted-by":"crossref","unstructured":"F Logman B Heeg MF Botteman. Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: application to the United KingdomBarcelona, SpainPresented at ECCO 14: the European Cancer Conference, 23\u201327 September 2007(Abstr 1146)","DOI":"10.1016\/S1359-6349(07)70665-1"},{"key":"10.1093\/annonc\/mdn164_bb0390","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdn164_bb0395","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1007\/BF03194355","article-title":"Diagnosis of osteoporosis","volume":"7","author":"Kanis","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdn164_bb0400","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdn164_bb0405","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/JBMR.040508","article-title":"Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA)","volume":"19","author":"Siris","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdn164_bb0410","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/jama.298.20.2389","article-title":"Factors associated with 5-year risk of hip fracture in postmenopausal women","volume":"298","author":"Robbins","year":"2007","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdn164_bb0415","first-page":"S107","article-title":"Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy\u2014First safety data from the AZURE trial (BIG01\/04)","volume":"100","author":"Coleman","year":"2006","journal-title":"Breast Cancer Res Treat"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/8\/1407\/627536\/mdn164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:43:07Z","timestamp":1624437787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419402597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0923753419402597"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn164","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}